At issue: Schizophrenia and rheumatoid arthritis: The negative association revisited

Schizophrenia Bulletin

Volumn 25, Issue 4, 1999, Pages 625-638

  Oken, Robert J ^a,b   Schulzer, Michael ^c  

^a New York Stt Inst Basic Res D ^*  (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Glutamatergic dysfunction pharmacology; Platelet activating factor system; Rheumatoid arthritis; Schizophrenia

Indexed keywords

GLUTAMIC ACID;

ADULT; ARTHRITIS; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; META ANALYSIS; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCHIZOPHRENIA; THROMBOCYTE ACTIVATION;

EID: 0033396319     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033407     Document Type: Article

References (78)

1. Abramson, S.B.; Korchak, H.; Ludewig, R.; Edelson, H.; Haines, K.A.; Levin, R.I.; Herman, R.; Rider, L.; and Weissman, G. Modes of action of aspirin-like drugs. Proceedings of National Academy of Sciences, 82:7227-7231, 1985.
2. Akbarian, S.; Kim, J.J.; Potkin, S.G.; Hetrick, W.P.; Bunney, W.E.; and Jones, E.G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Archives of General Psychiatry, 53:425-436, 1996.
3. Albrecht, V.; Abv-Issa, R.; Ratz, B.; Hattori, M.; Aoki, J.; Arai, H.; Inoue, K.; and Eichele, G. Platelet-activating factor acetylhydrolase expression and activity suggest a link between neuronal migration and platelet-activating factor. Developmental Biology, 180:579-593, 1996.
4. Allebeck, P.; Rodvall, Y.; and Wistedt, P. Incidence of rheumatoid arthritis among patients with schizophrenia, affective psychosis and neurosis. Acta Psychiatrica Scandinavica, 71:615-619, 1985.
5. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: The Association, 1987.
6. Baldwin, J.A. Schizophrenia and physical disease: A preliminary analysis of the data from the Oxford Record Linkage Study. In: Hemmings, G., ed. The Biochemistry of Schizophrenia and Addiction. Lancaster, England: MTP Press, 1980. pp. 42-50.
7. Bartha, R.; Williamson, P.C.; Drost, D.J.; Malla, A.; Carr, T.J.; Cortese, L.; Canaran, G.; Rylett, R.J.; and Neufeld, R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives of General Psychiatry, 54:959-965, 1997.
8. Bazan, N.G. A signal terminator. Nature, 374:501-502, 1995.
9. 2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochemical and Biophysical Research Communications, 241:630-635, 1997.
10. Blank, M.L.; Lee, Y.J.; Cress, E.A.; and Snyder, F. Stimulation of the de novo pathway for the biosynthesis of platelet-activating factor (PAF) via cytidyltransferase activation in cells with minimal endogenous PAF production. Journal of Biological Chemistry, 263:5656-5661, 1988.
11. Blank, M.L.; Smith, Z.L.; Cress, E.A.; and Snyder, F. Characterization of the enzymatic hydrolysis of acetate from alkylacetylglycerols in the de novo pathway of PAF biosynthesis. Biochemica et Biophysica Acta, 1042:153-158, 1990.
12. Brown, S. Excess mortality of schizophrenia: A metaanalysis. British Journal of Psychiatry, 171:502-508, 1997.
13. Bullmore, G.T.; Woodruff, P.W.R.; Wright, I.C.; Rabe-Hesketh, S.; Howard, R.J.; Shuriquie, N.; and Murray, R.M. Does dysplasia cause anatomical dysconnectivity in schizophrenia? Schizophrenia Research, 30:127-135, 1998.
14. Carlsson, M., and Carlsson, A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin, 16(3):425-432, 1990.
15. Clark, G.D.; Mizuguchi, M.; Antalffy, B.; Bames, J.; and Armstrong, D. Predominant localization of the LIS family of gene products to Cajal-Retzius cells and ventricular neuroepithelium in the developing human cortex. Journal of Neuropathology and Experimental Neurology, 56:1044-1052, 1997.
16. Cooper, H., and Hedges, L.V. The Handbook of Research Synthesis. New York, NY: Russell Sage, 1994. pp. 245-281, 400-408.
17. Deutsch, S.I.; Mastropaolo, J.; Schwartz, B.L.; Rosse, R.B.; and Morihisa, J.M. A glutamatergic hypothesis of schizophrenia: Rationale for pharmacotherapy with glycine. Clinical Neuropharmacology, 12:1-13, 1989.
18. Eastwood, S.L.; Burnet, P.W.J.; and Harrison, P.J. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study. Molecular Brain Research, 44:92-98, 1997.
19. Eaton, W.W. Epidemiology of Schizophrenia. Epidemiology Reviews, 7:109-121, 1985.
20. Eaton, W. W.; Hayward, C.; and Ram, R. Schizophrenia and rheumatoid arthritis: A review. Schizophrenia Research, 6:181-192, 1992.
21. Ehrentheil, O. Common medical disorders rarely found in psychotic patients. American Medical Association Archives of Neurology and Psychiatry, 77:178-186, 1957.
22. Ferguson, R.M.; Schmidtke, J.R.; and Simmons, R.L. Effects of psychoactive drugs on in vitro lymphocyte activation. In: Bergama, D., and Goldstein, A.L., eds. Neurochemical and Immunologic Components of Schizophrenia (Series: Birth Defects). Vol. 14, No. 5. New York, NY: Liss, 1978.
23. Fleiss, J.L. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: Wiley and Sons, 1981. pp. 90-96, 160-186.
24. Gattaz, W.F.; Beckman, H.; and Mendlewicz, J. HLA antigens and schizophrenia: A pool of two studies. Psychiatry Research, 5:123-128, 1981.
25. 2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids, 55:109-113, 1996.
26. 2 activity in schizophrenia: A replication study. Biological Psychiatry, 28:495-501, 1990.
27. Gattaz, W.F.; Kasper, S.; Ewald, R.W.; and Beckman, H. Arthropathies and schizophrenia. Lancet, II:536-537, 1980.
28. Ghosh, S., and Kopp, E. Response. Science, 270:2018-2019, 1995.
29. Goff, D.C., and Wine, L. Glutamate in schizophrenia: Clinical and research implications. Schizophrenia Research, 27:157-168, 1997.
30. Gowdy, J.M. Immunoglobulin levels in psychotic patients. Psychosomatics, 21:751-756, 1980.
31. Gregg, D. The paucity of arthritis among psychotic cases. American Journal of Psychiatry, 95:853, 1939.
32. Grilli, M.; Pizzi, M.; Memo, M.; and Spano, P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science, 274:1383-1385, 1996.
33. Hattori, M.; Adachi, H.; Tsujimoto, M.; Aral, H.; and Inoue, K. Miller-Dicker lissencephaly gene encodes a subunit of brain platelet-activating factor. Nature, 370:216-218, 1994.
34. Hedges, L.V., and Olkin, I. Statistical Methods for Metaanalysis. San Diego, CA: Academic Press, 1985. pp. 304-307.
35. Ho, Y.S.; Swenson, L.; Derewenda, U.; Serre, L.; Wei, Y.; Dauter, Z.; Hattori, M.; Adachi, T.; Aoki, J.; Arai, H.; Inoue, K.; and Derewenda, Z. Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer. Nature, 385:89-93, 1997.
36. Horrobin, D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research, 30:193-208, 1998.
37. Horrobin, D.F.; Glen, A.I.; and Hudson, C.J. Possible relevance of phospholipid abnormalities and genetic interactions in psychiatric disorders: The relationship between dyslexia and schizophrenia. Medical Hypotheses, 45:605-613, 1995.
38. Howat, D.; Desa, F.; Chander, C.; Moore, A.; and Willoughby, D. The synergism between platelet-activating factor and interleukin 1 on cartilage breakdown. Journal of Lipid Mediators, 2:143-149, 1990.
39. Johansen, H.; Chagani, K.; Lessard, S.; and Nair, C. Person-based information from Canadian hospital discharge data. Leadership, September/October: 27-32, 1996.
40. Jones-Brando, L.V.; Buthod, J.L.; Holland, L.E.; Yolken, R.H.; and Torrey, E.F. Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1. Schizophrenia Research, 25(1):63-70, 1997.
41. Krakowski, A.J.; Rydzynski, A.; Jarosz, M.; and Engelsmann, F. Prevalence of psychosomatic disorders in schizophrenic patients in Poland. In: Krakowski, A.J., and Kimbal, R., eds. Psychosomatic Medicine: Theoretical, Clinical and Transcultural Aspects. New York, NY: Plenum Press, 1983. pp. 69-78.
42. LaFosse, J.M., and Mednick, S.A. A neurodevelopmental approach to schizophrenia research. In: Mednick, S.A.; Cannon, T.D.; Barr, C.E.; and LaFosse, J.M., eds. Developmental Neuropathology of Schizophrenia. New York, NY: Plenum Press, 1991. pp. 211-225.
43. Lee, T.; Lenihan, D.J.; Malone, B.; Roddy, L.L.; and Wasserman, S.I. Increased biosynthesis of platelet-activating factor in activated human eosinophils. Journal of Biological Chemistry, 259(9):5526-5530, 1984.
44. Lovett, C.L.; Ulrich, J.T.; Simms, B.G.; and Goldstein, A.L. Effects of chlorpromazine on antibody production in vitro. In: Bergama, D., and Goldstein, A.L., eds. Neurochemical and Immunologic Components of Schizophrenia (Series: Birth Defects). Vol. 181. New York, NY: Liss, 1978. pp. 387-395.
45. McGeer, P.L.; McGeer, E.G.; Rogers, J.; and Sibley, J. Anti-inflammatory drugs and Alzheimer disease. [Letter.] Lancet, 335:1037, 1990.
46. McMillan, R.M.; Foster, S.J.; and Shaw, J.S. Approaches to novel antiarthritic drugs by modulation of the arachidonic acid cascade. In: Henderson, B.; Edwards, J.C.; and Pettipher, E.R., eds. Mechanisms and Models in Rheumatoid Arthritis. San Diego, CA: Academic Press, 1995. pp. 283-300.
47. Mellor, J.E.; Laugharne, J.D.G.; and Peet, M. Omega-3 fatty acid supplementation in schizophrenic patients. Human Psychopharmacology, 11:39-46, 1996.
48. Mellsop, G.W.; Koadlow, L.; Syme, J.; and Whittingham, S. Absence of rheumatoid arthritis in schizophrenia. Australian and New Zealand Journal of Medicine, 4:247-252, 1974.
49. Mohamed, S.N.; Merskey, H.; Kazarion, S.; and Disney, T.F. An investigation of the possible inverse relationship between the occurrence of rheumatoid arthritis, osteoarthritis, and schizophrenia. Canadian Journal of Psychiatry, 27:381-383, 1982.
50. Nakagawa, Y.; Sugai, M.; Karasawa, K.; Tokumura, A.; Tsokatani, H.; Setaka, M.; and Nojima, S. Possible influence of lysophospholipase on the production of 1-acyl-2-acetylglycerophosphocholine in macrophages. Biochimica et Biophysica Acta, 1126(3):277-285, 1992.
51. Nissen, H.A., and Spencer, K.A. The psychogenic problem (endocrinal and metabolic) in chronic arthritis. New England Journal of Medicine, 21:567-581, 1936.
52. Nowakowski, R.S. Neuronal migration and differentiation during normal and genetically perturbed development of the hippocampal formation. In: Mednick, S.A.; Cannon, T.D.; Barr, C.E.; and LaFosse, J.M., eds. Developmental Neuropathology of Schizophrenia. New York, NY: Plenum Press, 1991. pp. 29-60.
53. Olney, J.W., and Farber, N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry, 52:998-1007, 1995.
54. Osterberg, E. Schizophrenia and rheumatic disease. Acta Psychiatrica Scandinavica, 58:339-359, 1978.
55. Peet, M.; Laugharne, J.D.G.; and Mellor, J. "Double-blind trial of n-3 fatty acid supplementation in the treatment of schizophrenia." Paper presented at the International Conference on Schizophrenia Research, Colorado Springs, CO, April 1997.
56. Peet, M.; Laugharne, J.D.G.; Mellor, J.; and Ramchand, C.N. Essential fatty acid deficiency in erythrocyte membrane from chronic schizophrenic patients, and the clinical effect of dietary supplementation. Prostaglandins, Leukotrienes and Essential Fatty Acids, 55:71-75, 1996.
57. Pettipher, E.R., and Blake, S. Antigen-induced arthritis. In: Henderson, B.; Edwards, J.C.; and Pettipher, E.R., eds. Mechanisms and Models in Rheumatoid Arthritis, San Diego, CA: Academic Press, 1995. pp. 457-470.
58. Pilkington, T.L. The coincidence of rheumatoid arthritis and schizophrenia. Journal of Nervous and Mental Disorders, 124:604-606, 1956.
59. Puri, B.K., and Steiner, R. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Archives of General Psychiatry, 55:188-189, 1998.
60. Ramsay, R.A.; Ananth, J.; Engelsmann, F.; Krakowski, A.J.; Witkower, E.D.; and Ghadirian, A.M. Schizophrenia and psychosomatic illness. Journal of Psychosomatic Research, 26:33-42, 1982.
61. Rosenthal, R. The file drawer problem and tolerance for null results. Psychology Bulletin, 86:1165-1168, 1979.
62. Ross, W.D.; Hay, J.; and McDowall, M.F. The association of certain vegetative disturbances with various psychoses. Psychosomatic Medicine, 12:170-183, 1950.
63. Rothermich, N.O., and Philips, V.K. Rheumatoid arthritis in criminal and mentally ill populations. Arthritis and Rheumatism, 6:639-640, 1963.
64. Sachdev, P. Schizophrenia-like psychosis and epilepsy: The status of the association. American Journal of Psychiatry, 155:325-336, 1998.
65. Sapir, T.; Elbaum, M.; and Reiner, O. Reduction of microtubule catastrophe events by LIS1, a platelet-activating factor acetylhydrolase subunit. EMBO Journal, 16:6977-6984, 1997.
66. Snyder, F. Metabolism of platelet activating factor and related ether lipids: Enzymatic pathways, sub-cellular sites, regulation, and membrane processing. Progress in Clinical and Biological Research, 282:57-72, 1988.
67. Spector, T.D. Rheumatoid arthritis. Rheumatic Disease Clinics of North America, 16:513-537, 1990.
68. Tjoelker, L.W.; Wilder, C.; Eberhardt, C.; Stafforini, D.M.; Dietsch, G.; Schimpf, B.; Hooper, S.; Trong, H.L.; Cousens, L.S.; Zimmerman, G.A.; Yamada, Y.; McIntyre, T.M.; Prescott, S.M.; and Gray, P.W. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature, 374:549-553, 1995.
69. Trevathan, R.D., and Tatum, J.C. Rarity of concurrence of psychosis and rheumatoid arthritis in individual patients. Journal of Nervous and Mental Disorders, 120:83-84, 1954.
70. Ulas, J., and Cotman, C.W. Excitatory amino acid receptors in schizophrenia. Schizophrenia Bulletin, 19(1):105-117, 1993.
71. Villani, A.; Cirino, N.M.; Baldi, E.; Kester, M.; McFadden, E.R., Jr.; and Panuska, J.R. Respiratory synctial virus infection of human mononuclear phagocytes stimulates synthesis of platelet-activating factor. Journal of Biological Chemistry, 266:5472-5479, 1991.
72. Vinogradov, S.; Gottesman, I.L.; Moises, H.W.; and Nicol, S. Negative association between schizophrenia and rheumatoid arthritis. Schizophrenia Bulletin, 17:669-678, 1991.
73. Wachtel, H., and Turski, L. Glutamate: A new target in schizophrenia? Trends in Pharmacological Sciences, 11:219-220, 1990.
74. Weiden, P.J., and Olfson, M. Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21(3):419-429, 1995.
75. World Health Organization. Mental Disorder: Glossary and Guide to Their Classification in Accordance with the Ninth Revision of the International Classification of Diseases. Geneva, Switzerland: The Organization, 1978.
76. Wright, P.; Donaldson, P.T.; Underhill, J.A.; Choudhuri, K.; Doherty, D.G.; and Murray, R.M. Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia. American Journal of Psychiatry, 153:1530-1533, 1996a.
77. Wright, P.; Sham, P.C.; Gilvarry, C.M.; Jones, P.B.; Cannon, M.; Sharma, T.; and Murray, R.M. Autoimmune diseases in the first degree relatives of schizophrenic and control subjects. Schizophrenia Research, 20:261-267, 1996b.
78. Zarrabi, M.H.; Zucker, S.; and Miller, F. Immunologic and coagulation disorders in chlorpromazine-treated patients. Annals of Internal Medicine, 91:194-199, 1979.